Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Homologous recombination repair and breast cancer gene testing in prostate cancer: expert perspectives and practical guidance on best practice from sample acquisition to biomarker-informed clinical decision-making.

Frontiers in oncology·2026
Same author

Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status.

British journal of cancer·2026
Same author

The Value of Progression-Free Survival in the Perspective of Patients with Multiple Myeloma and Treating Physicians: Research Findings from the US, EU4, UK, Brazil, and Japan.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Targeted Radiation, Unintended Evolution.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

[Update of S3 guideline on metastatic prostate cancer-guideline recommendations and expert consensus].

Urologie (Heidelberg, Germany)·2026
Same author

Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).

The oncologist·2026

相关实验视频

Updated: Jun 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

治疗模式在雄激素受体通路抑制剂经验丰富的患有转移性割耐性前列腺癌的患者中:全球现实研究

Gunhild von Amsberg1, Alison Bulkley2, Marc DeCongelio2

  • 1University Cancer Center Hamburg and Martini-Klinik, Hamburg, Germany.

Clinical genitourinary cancer
|March 10, 2026
PubMed
概括

序列雄激素受体通路抑制剂 (ARPI) 的使用在初始ARPI治疗后转移性割抵抗性前列腺癌 (mCRPC) 中很常见. 治疗选择,包括连续的ARPI或化疗,取决于患者的表现状态.

关键词:
阿比拉特罗尼是一个人多塞塔克塞尔 (Docetaxel) 是一种药物.酵素胺是什么 酵素胺是什么现实世界的证据.治疗顺序的顺序处理.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K

相关实验视频

Last Updated: Jun 7, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

9.7K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 临床医学 临床医学

背景情况:

  • 雄激素受体通路抑制剂 (ARPI) 越来越多地用于前列腺癌早期治疗阶段.
  • 在前转移性割抵抗性前列腺癌 (mCRPC) 中使用ARPI后治疗模式的现实数据有限.
  • 这项研究考察了对mCRPC患者的当代治疗策略,这些患者之前曾接触过ARPI.

研究的目的:

  • 在ARPI经验丰富的mCRPC患者中描述现实世界的治疗模式.
  • 分析初始ARPI治疗后的治疗序列.
  • 确定影响该群体治疗选择的因素.

主要方法:

  • 从2023年8月至10月对1014名mCRPC患者进行了回顾性,非干预性研究.
  • 医生根据先前接受ARPI和mCRPC治疗的患者的病历完成了电子病例报告.
  • 在ARPI经验丰富的患者中,mCRPC的第一个治疗方法被定义为索引线.

主要成果:

  • 82.6%的患者在mCRPC前接受了初始ARPI;17.4%接受了第一线mCRPC治疗.
  • 索引线治疗包括另一个ARPI (48.4%) 或dcetaxel (35%).
  • 常见的序列是阿比拉→多 (16.1%) 和阿比拉→ (10.9%). 在ECOG 0-1 (42%-46%) 和ECOG ≥2 (29%) 的患者中,塔克桑治疗更常见.

结论:

  • 连续使用ARPI是一种常见的国际做法,可能是为了减轻化疗毒性.
  • 顺序性ARPI和化疗之间的治疗选择因患者的表现状况而异.
  • 需要针对ARPI耐药前列腺癌的新疗法.